ERBB2 and breast cancer: The MonarcHER trial, which included 273 patients with HER2-positive/HR-positive advanced BC, found that the combination of fulvestrant, abemaciclib, and trastuzumab improved patient outcomes compared to trastuzumab plus chemotherapy [36].